EXACT Sciences — Investor Presentation (September 2008)
17 slides from EXACT Sciences's investor presentation, Sep 4, 2008
Slide 1: Driving Innovation In Early Cancer Detection
Corporate Presentation Driving Innovation In Early Cancer Detection September 3, 2008
Slide 2: Safe Harbor
1 Safe Harbor Certain matters contained in this presentation, other than historical information, consist of forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 relating to, among other things, our expectations concerning the
Slide 3: EXACT Sciences Corp. Fast Facts
2 EXACT SCIENCES CORP. Fast Facts • Founded in 1996 by Stan Lapidus, founder of Cytyc • IPO in 2001, Secondary Offering in 2004 • Headquartered in Marlborough, MA • 113 patents worldwide • Outside R&D development engines (Johns Hopkins, Case Western Reserve) • 4 employees
Slide 4: Leadership Team
3 Leadership Team • 20+ years in assay development and clinical laboratory services Kris Durkee, PhD VP, Research & Development • 20+ years in biotechnology, clinical lab services, and reimbursement Barry Berger, MD CMO • 15+ years public biotechnology company and financial experience Charles Carell
Slide 5: Fundamental Breakthroughs at EXACT Sciences – Last Months
4 Fundamental Breakthroughs at EXACT Sciences – Last 12 mos. • New non-invasive two-marker test (V2) (83%/82%) • Newest detection technology from JHU to EXACT: 92% sensitivity reported in Gastroenterology, August 2008 • Endorsement of technology by key medical societies, including the American Cance
Slide 6: Market Overview
5 Market Overview
Slide 7: Colorectal Cancer is Among the Deadliest Cancers
6 Colorectal Cancer is Among the Deadliest Cancers Cervix Ovary Prostate Pancreas Breast Colorectal Lung 2nd Most Deadly Cancer in the U.S. U.S. Mortality Number of Deaths Annually Source: ACS: Cancer Facts and Figures 2008 3,870 15,520 28,660 34,290 40,930 49,960 162,000
Slide 8: Colorectal Cancer Highly Treatable if Detected Early
7 Source: ACS website Cancer.org; AGA website Colorectal Cancer Highly Treatable if Detected Early Late Early Distribution of Colorectal Cancer Detection % of Patients Detected $25K-$40K $150K-$250K Treatment Cost Per Patient Diagnosis Stage Clear Outcomes and Cost Benefits to Early Screening 61% 39
Slide 9: Significant Unmet Need for Early Screening and Detection
8 Significant Unmet Need for Early Screening and Detection • Broad population of test “refusers” – Invasiveness – Bowel preparation – Annual testing requirements – Inconvenient collection methods • No successful mass screening test exists • 50%+ of 90 million eligible people age 50+ have never been
Slide 10: Our Solution
9 Our Solution
Slide 11: EXACT "Owns" this Opportunity
10 EXACT “Owns” this Opportunity • Only company that “owns” standard-of-care guidelines category from ACS for colorectal cancer • EXACT’s patents required for sDNA testing service for colorectal cancer screening CT Colonography Double Contrast Barium Enema Flexible Sigmoidoscopy Colonoscopy Fecal Oc
Slide 12: sDNA
11 sDNA • Detects DNA-based abnormalities associated with colorectal cancer – Direct measure, unlike FOBT • Why patients prefer sDNA: – No bowel preparation – No medication or dietary restrictions – No anesthesia or sedation – No lost time off from work – Collected simply at home – Test every 3-5 yr
Slide 13: Clinically Validated Technology with Continued Performance Improvements
12 Clinically Validated Technology with Continued Performance Improvements 92% 83% (82%) 72-77% (83-94%) 70% (95%) 52% (95%) Sensitivity (Specificity) V2 test: Clinical Gastroenterology and Hepatology, Itzkowitz S, 2007 V1 test: Journal of Molecular Diagnostics, Whitney D, 2004 Proof-of-Concept test
Slide 14: Commercialization Strategy
13 Commercialization Strategy LabCorp Relationship • Leverage LabCorp marketing, sales team and infrastructure – LabCorp launches ColoSureTM July, 2008 based on EXACT’s intellectual property – 15% royalty to EXACT • ColoSure currently being offered at a list price of $200 to LabCorp payor clients an
Slide 15: World-Class Collaborations
14 World-Class Collaborations • Past research on aerodigestive cancers • “High prevalence supracolonic aerodigestive cancers may also be detected by sDNA” – Journal Cancer, March 2008 • Gene marker patent for V2 test through 2024, upon issuance • Exclusive worldwide license to key colorectal cancer
Slide 16: Key Assets
15 Key Assets • 15% royalty from LabCorp, July 2008 – Sales force training at LabCorp reported as underway for 1,000-person salesforce – Significant advantages over existing screening paradigms • EXACT maintains broad, commercially exploitable rights in its technology beyond LabCorp (US and Int’l) –
Slide 17: Building Blocks in Place for Success
16 Building Blocks in Place for Success Highly differentiated value proposition Significant unaddressed need in underserved market Strong clinical validation External R&D engines in place Endorsed by American Cancer Society International guidelines endorsement received Sound econometric rationale Co
Exact Sciences — Investor Presentation (September 2008) on 6ix